787–798; (d) K. Siddiquee, S. Zhang, W. C. Guida,
M. A. Blaskovich, B. Greedy, H. R. Lawrence, M. L. Yip,
R. Jove, M. M. McLaughlin, N. J. Lawrence, S. M. Sebti and
J. Turkson, Proc. Natl. Acad. Sci. U. S. A., 2007, 104, 7391–7396;
(e) P. K. Mandal, W. S.-L. Liao and J. S. McMurry, Org. Lett.,
2009, 11, 3394–3394.
4 (a) M. Chatterjee-Kishore, F. V. D. Akker and G. R. Stark, Trends
Cell Biol., 2000, 10, 106–111; (b) D. E. Levy and J. E. Darnell, Jr,
Nat. Rev. Mol. Cell Biol., 2002, 3, 651–662.
5 (a) J. Kuriyan and D. Cowburn, Annu. Rev. Biophys. Biomol.
Struct., 1997, 26, 259–288; (b) T. Pawson and R. Linding, FEBS
Lett., 2005, 579, 1808–1814.
Fig. 2 (a) IC50 of the two inhibitors determined by fluorescence
polarization (FP) experiments. (b) Relative % of T47D cell viability
in the presence of the two inhibitors, I2 (500 mM, 250 mM and 125 mM)
and I1 (250 mM). Negative control: DMSO only (0.56% final conc.).
Positive control: staurosporine (STS, 500 nM). ꢁ SD was based on
average of two independent experiments.
6 S. Zhou, S. E. Shoelson, M. Chaudhuri, G. Gish, T. Pawson,
W. G. Haser, F. King, T. Roberts, S. Ratnofsky, R. J. Lechleider,
B. G. Neel, R. B. Birge, J. E. Fajardo, M. M. Chou, H. Hanafusa,
B. Schaffhausen and L. C. Cantley, Cell, 1993, 72, 767–778.
7 (a) E. A. Lunney, K. S. Para, R. J. Ronald, C. Humblet,
J. H. Fergus, J. S. Marks and T. K. Sawyer, J. Am. Chem. Soc.,
1997, 119, 12471–12476; (b) T. K. Sawyer, Biopolymers, 1998, 47,
243–261; (c) W. C. Shakespeare, Curr. Opin. Chem. Biol., 2001, 5,
409–415; (d) R. Sundaramoorthi, N. Kawahata, M. G. Yang,
W. C. Shakespeare, C. A. Metcalf III, Y. Wang, T. Merry,
C. J. Eyermann, R. S. Bohacek, S. Narula, D. C. Dalgarna and
T. K. Sawyer, Biopolymers, 2003, 71, 717–729; (e) Y.-Q. Long,
T. Xue, Y.-L. Song, Z.-L. Liu, S.-X. Huang and Q. Yu, J. Med.
Chem., 2008, 51, 6371–6380; (f) T. R. Burke and K. Lee,
Acc. Chem. Res., 2003, 36, 426–433.
8 H. Yu and R. Jove, Nat. Rev. Cancer, 2004, 4, 97–105.
9 K. E. Muratore and P. A. Cole, ACS Chem. Biol., 2007, 2,
454–456.
10 (a) G. Liu, Z. Xin, Z. Pei, P. J. Hajduk, C. A. Zapatero,
C. W. Hutchins, H. Zhao, T. H. Lubben, S. J. Ballaron,
D. L. Haasch, W. Kaszubska, C. M. Rondinone,
J. M. Trevillyan and M. R. Jirousek, J. Med. Chem., 2003, 46,
4232–4235; (b) R. Srinivasan, M. Uttamchandani and S. Q. Yao,
Org. Lett., 2006, 8, 713–716; (c) R. Srinivasan, L. P. Tan, H. Wu
and S. Q. Yao, Org. Lett., 2008, 10, 2295–2298.
modifications of other portions in I1, either rationally or
combinatorially.3
In summary, we have synthesized a novel unnatural amino
acid which mimics phosphotyrosine but possesses better cell
permeability and hydrolytic stability. Its incorporation into a
known STAT3 SH2 domain inhibitor has confirmed our
design principle. Future work will focus on incorporation of
this amino acid into other pTyr-containing biologically active
compounds. This new pTyr mimic, together with other newly
developed approaches,13 will provide expanded chemical tools
for future studies of PTP biology.
Funding support was provided by the tier-2 grant
(R-143-000-394-112) from the Ministry of Education of Singapore.
Notes and references
11 (a) F. Himo, T. Lovell, R. Hilgraf, V. V. Rostovtsev,
L. Noodleman, K. B. Sharpless and V. V. Fokin, J. Am. Chem.
Soc., 2005, 127, 210–216; (b) M. B. Soellner, K. A. Rawls,
C. Grundner, T. Alber and J. A. Ellman, J. Am. Chem. Soc.,
2007, 129, 9613–9615.
12 This value is slightly higher than the reported 42 mM obtained from
a DNA-binding assay,3a likely due to the difference in the assay
type.
13 (a) K. A. Kalesh, L. P. Tan, K. Liu, L. Gao, J. Wang and
S. Q. Yao, Chem. Commun., 2010, 46, 589–591; (b) L. P. Tan,
H. Wu, P.-Y. Yang, K. A. Kalesh, X. Zhang, M. Hu, R. Srinivasan
and S. Q. Yao, Org. Lett., 2009, 11, 5102–5105; (c) H. Sun,
L. P. Tan, L. Gao and S. Q. Yao, Chem. Commun., 2009, 677–679.
1 (a) J. A. Wells and C. L. McLendon, Nature, 2007, 450, 1001–1009;
(b) H. Yin and A. D. Hamilton, Angew. Chem., Int. Ed., 2005, 44,
4130–4163.
2 (a) T. Berg, Angew. Chem., Int. Ed., 2003, 42, 2462–2481;
(b) A. J. Wilson, Chem. Soc. Rev., 2009, 38, 3289–3300.
3 (a) J. Turkson, J. S. Kim, S. Zhang, J. Yuan, M. Huang, M. Glenn,
E. Haura, S. Sebti, A. D. Hamilton and R. Jove, Mol. Cancer
Ther., 2004, 3, 261–269; (b) J. Turkson, D. Ryan, J. S. Kim,
Y. Zhang, Z. Chen, E. Haura, A. Laudano, S. Sebti,
A. D. Hamilton and R. Jove, J. Biol. Chem., 2001, 276,
45443–45455; (c) K. A. Z. Siddiquee, P. T. Gunning, M. Glenn,
W. P. Katt, S. Zhang, C. Schroeck, S. M. Sebti, R. Jove,
A. D. Hamilton and J. Turkson, ACS Chem. Biol., 2007, 2,
ꢀc
This journal is The Royal Society of Chemistry 2010
2982 | Chem. Commun., 2010, 46, 2980–2982